Good you I and then results an afternoon, thank on review and XXXX first update business financial our quarter recent update pipeline call. our will activities. with for begin and joining TRACON's
discuss ended that, XXXX. March Following will Brown, for results Chief our financial Scott XX, the Officer, Financial our three months
will we conclude Finally, your by questions. taking
ENVA an with ENVASARC on our a with in progress and ongoing evaluating update continued pivotal the combination trial, I'll as Yervoy. agent single begin with
the refractory to have or accruing patients XXX more We occur XXXX. the in exceed anticipated enrolled than the completion now at sites treated of and Accrual XX into XX U.S. ENVA before is of patients which enrollment U.K. dose with one end is site to the UPS, of ENVASARC, and the XXX-milligram in MFS, continues at projections
the Yervoy from ENVA. ENVA, at trial of previous and efficacy DMC were review in pre-specified dose patients safety patients the efficacy noted instituted rule. the that with included only and patients by XXX-milligram a weight reviewed reported Responses independent patients. two evaluations announced safety we dose the that review who in cohorts, ENVASARC single was cohort on-treatment weeks two into tolerated XXX-milligram DMC than combination December, enrolled ENVA of more was in with interim of completed following a efficacy central The event rate objective regardless the assessed In well XX related each data the response XX interim of blinded serious double-digit minimum XX in treated each of in scans. monotherapy satisfied from data of adverse that futility at the of
planned trial as dose. the the recommended DMC The ENVA XXX-milligram at continue
responses, in objective response out study at Votrient double-digit rate the of treatment is we the that with blinded either patients time or is rate, satisfies for reminder, interim drug a of response only rate of response a objective the XX.XX% X% meaningful, primary an and a of to independent confirmed Notably, X response box for warning MFS. liver review, to endpoint UPS are is or Votrient, of by endpoint a cohort Therefore, endpoint the indicating achieve rate analysis central toxicity. objective with track each exceed the objective the RECIST XX on the primary primary defines a response black of statistically As in approved study. fatal that refractory by level cohort the
Our goal in efficacious ENVASARC, therefore, Votrient. both more safer is to is demonstrate that than ENVA and
quarter. patients safety third robust efficacy blinded been for patients ENVASARC the accrual review prevent that of the we will for least three by XX interim Central XX at cohort, evaluation and are DMC efficacy two data to second from more followed to scans DMC analysis on the for in in each perform on-study Given the who the into track mandated review. Independent have protocol than trial, time, the At months
three committee assessment, apply rule order efficacy least accrual XX a interim continue in During cohort. will in that futility requires to the into at responses that patients
available review of not efficacy in include have December, assess each scans. safety in occurred the data of that DMC a the mandated be every last The the quarter not Since scheduled second review there This in be and minimum to DMC months. addition review review Ad the review safety an in the six available will third and all stipulates charter quarter, of efficacy the DMC rule at will cohorts. In DMC two formal will and a reviewed quarter. central futility Hoc invoke second in efficacy meeting to a we
UPS refractory Based ENVA responses in are MFS, BLA rate strategy Furthermore, FDA for a on the rate we as in determine approach a as for response single-agent to either combination the plan or checkpoint soon inhibitors Yervoy. to and targeting filing data XX% ENVA in cohort. from X trials we up XX% with of response discuss a we other to
As provide that a in drug in for that UPS based lines and on received received and in of Fast These regulatory or progressed and sarcoma the observed review reminder, subtypes have designation commercialization of might MFS therapy, of sarcoma activity expedite we tissue soft important have Track designation advantages one ENVASARC. prior designations have on ENVA orphan ENVA. two
have dosed treatment initiated therapy. received of open, product CRO-independent development we patients, prior patients sites from including of YHXXX best-in-class Last licensed research. platform who for approved patients on TRACON's we have multiple Moving initiate trial. CTLA-X sarcoma site In potentially IND Eucure the in clinical October to our first XXXX; YHXXX, a are the the that in I/II of of not August, to and FDA inhibitor, October, a using Several antibody XXXX. our now we trial Biopharma Phase checkpoint second the
Our demonstrated Phase and two trials a recommended initial Eucure. single in with toripalimab. combination II YHXXX the from two trials the our These leverages of completed dose trial I partner, agent by Phase PD-X data as antibody, conducted YHXXX
doxorubicin sarcoma. trial sponsored the current care Our of standard I/II triplet for that chemotherapy treatment evaluate includes as Phase doxorubicin clinical YHXXX, a frontline and will ENVA is
of of doublet the I YHXXX the to report and tolerability expect trial as the well combination therapy the Phase data as ENVA Phase year. of I in portion doxorubicin. The includes that assesses half we second this And the of the triple
Thereafter, the rates of standard response treatment, subtypes II of superior intent historical the rate Phase portion will demonstrating of to rare data sarcoma agents. combination using compared assess trial and care the with response the in to common
rate therapy rate compared to doxorubicin. sarcoma, chemotherapy checkpoint to the to response we alveolar the where doublet rare historical effective, for the highly response rate single-agent of we XX% inhibition. of XX% to response plan the to soft not agent triple case ENVA like In rates of intend and compare and and the leiomyosarcoma is assess In sarcoma single part YHXXX liposarcoma, chemotherapy chondrosarcoma or study response subtypes historical to of
sarcoma One and of is combination the best of subtypes doxorubicin. to I/II the YHXXX that of respond determine Phase ENVA, the objectives this trial of to
pivotal ENVA, benefit. positive Assuming the of results a trial in a survival require randomized the ENVASARC FDA will potential trial and demonstrate accelerated trial to approval
as data this enroll I/II the point. to trial sarcoma We single-agent will Phase post-approval with compare as to expect expected subtypes UPS trial PFS be combination Phase to trial earlier. patients described shown ENVA and doxorubicin YHXXX, III to and end would from with based on I triple other the doxorubicin as triplet the therapy with respond MFS well of This that
a from accrual prior the FDA with design BLA for initiate our submission sarcoma planned in discuss ENVA and to the approval frontline based expect of data ENVASARC. accelerated trial on refractory to We of
ENVA revenue annual and the rare peak solely goal parity with strategic of is two revenues MFS not in in in pricing to in-licensed is the sarcoma in ENVA the demonstrated. UPS Our important forecasted to therapies million potential subtypes $XXX immuno-oncology It inhibition is in together sales million at initial in expected sarcoma. where annual understand indications $XXX sarcoma refractory of commercialize and the is the activity checkpoint
and with the Our marking sarcoma part clinical be by indications. ENVA opportunity combination revenue would for Moreover, patients designed is believe together development treatment benefit seeking of settings broadly YHXXX create total significantly sarcoma. neoadjuvant in to enhanced adjuvant ENVA supplemental sarcoma-driven a we in by TRACON's as and strategy the front-line sales to
II In The and trial checkpoint by benefit Phase The fund chemoradiation. non-small National combination initiated damage durvalumab that randomized we will Cancer of TRCXXX addition in consolidated trial, three, a has therapy X-arm followed inhibitors, non-squamous, are standard repair assess cell DNA, care Institute TRCXXX. lung to to cisplatin of our pemetrexed, maintenance patients of TRCXXX stage in two of NCI pleased to treatment. enroll continues our the development inhibitor, treatment radiation to XX with cancer current adding assessing the
to PFS, is in trial expected an enrollment, initiated U.S. results was to the improvement the year and open one in in detect final are designed XXXX. XXXX of for sites endpoint which the are primary XX%. XX% trial at from Multiple and PFS in is The
favor on in amount update On the $XX Chamber approximately with an our award were XXth, we aggregate arbitration rendered our to Next, I-Mab. of Commerce certain and provide of I in million. for April TRACON will International ruled the Tribunal an informed claims
findings, legal fourth fees are awarded TJXXXX which trial XXXX, the TRACON a January, as and award declared and terminated. now TRACON. both vice costs Interest arbitration thet agreement tribunal entitled the other of to also complete plus and The binding the to nine agreement pursuant Among in $X to made million is
funds under the and awarded will promptly payment digit did on agreements. interest threshold expect award not we pre-specified the entered the into amounts. non-recourse The any high in single and not receive financing additional agreement therefore We XXXX, a exceed includes award under December, such the
the is challenging important. the capital markets, award Given arbitration
collected given accompany the into Our capital expected proceeds the our efficiency award XXXX. and cash net current when early to from company are into funds fund three quarter arbitration
Our when including million to of terms is provide at effective, discretion registration and further the of a with be equity all line are declared by $XX conditions to That request entered filed the compliance robust ENVASARC accrual $X Park extended can runway with our that may Pivotal into credit to million Lincoln further the recently statement at we yields the and our support commencement subject its met, trial. and Capital. resale line equity
pipeline opportunities expect clinical who we for supplement infrastructure. us our reporting management, most given our enabled noted one partner, an In collaboration to through advanced independent have company development we the trial be our of with position in we trials to to as ideal product capital system we development clinical trials multiple As an and believe safety organizations. platform, particular, conduct our cash through and team would multiple management a data past, CRO further believe positions that the emerging ability plans efficient using execute
At update Scott this an provide our financials. time, on will
